Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD2 | Q9NRG4 | 2/20 | 0.33 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.31 |
| ▸ | SLC22A12 | Q96S37 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL875043 | 0.75 | SMYD2 (0.35) | SMYD2FFAR1 | |
| SCHEMBL12151761 | 0.73 | SMYD2 (0.34) | SMYD2KDM4EALDH1A1 | |
| SCHEMBL3544323 | 0.72 | PTGER4 (0.33) | SMYD2 | |
| SCHEMBL7791522 | 0.72 | NAAA (0.33) | SLC22A12 | |
| SCHEMBL14183240 | 0.71 | SMYD2 (0.33) | SMYD2 | |
| SCHEMBL3879562 | 0.71 | SMYD2 (0.33) | SMYD2 | |
| SCHEMBL1314001 | 0.70 | AGXT (0.42) | SMYD2ALDH1A1 | |
| SCHEMBL11937489 | 0.70 | TSHR (0.48) | FFAR1KDM4E | |
| SCHEMBL4822404 | 0.70 | PDCD1 (0.34) | SMYD2 | |
| SCHEMBL9566297 | 0.70 | IDO1 (0.33) | SMYD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9023882-B2 | 5-membered nitrogen containing heterocyclic derivatives and pharmaceutical compositions comprising the same | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2015-05-05 | — | — | US | disclosed |
| US-9023882-B2 | 5-membered nitrogen containing heterocyclic derivatives and pharmaceutical compositions comprising the same | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2015-05-05 | — | — | US | disclosed |
| US-9023882-B2 | 5-membered nitrogen containing heterocyclic derivatives and pharmaceutical compositions comprising the same | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2015-05-05 | — | — | US | disclosed |
| CN-101679244-B | 5-membered heterocyclic derivative and use thereof for medical purposes | KISSEI PHARMACEUTICAL | 2014-01-01 | — | — | CN | disclosed |
| US-20120289506-A1 | 5-MEMBERED NITROGEN CONTAINING HETEROCYCLIC DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2012-11-15 | — | — | US | disclosed |
| US-20120289506-A1 | 5-MEMBERED NITROGEN CONTAINING HETEROCYCLIC DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2012-11-15 | — | — | US | disclosed |
| US-8227500-B2 | 5-membered nitrogen containing heterocyclic derivatives and pharmaceutical compositions comprising the same | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2012-07-24 | — | — | US | disclosed |
| US-8227500-B2 | 5-membered nitrogen containing heterocyclic derivatives and pharmaceutical compositions comprising the same | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2012-07-24 | — | — | US | disclosed |
| US-20100227864-A1 | 5-MEMBERED HETEROCYCLIC DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2010-09-09 | — | — | US | disclosed |
| US-20100227864-A1 | 5-MEMBERED HETEROCYCLIC DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2010-09-09 | — | — | US | disclosed |
| CN-101679244-A | 5-membered heterocyclic derivative and use thereof for medical purposes | KISSEI PHARMACEUTICAL | 2010-03-24 | — | — | CN | disclosed |
| EP-2133331-A1 | 5-MEMBERED HETEROCYCLIC DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES | Kissei Pharmaceutical Co., Ltd. (JP) | 2009-12-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100227864-A1 | 5-MEMBERED HETEROCYCLIC DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES | XDH, DAO, CBR1 | SMYD2 478/4885FFAR1 1557/4885SLC22A12 259/4885 |
| US-20120289506-A1 | 5-MEMBERED NITROGEN CONTAINING HETEROCYCLIC DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | XDH, DAO, DDO | SMYD2 1092/4885FFAR1 1549/4885SLC22A12 504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.